We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

YSG:NYSEYatsen Holding Limited Analysis

Data as of 2026-05-12 - not real-time

$2.89

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Yatsen Holding (YSG) is trading at $2.89, well under its 20‑day ($3.02), 50‑day ($3.32) and 200‑day ($5.90) simple moving averages, signaling a sustained bearish price environment. The stock sits just above the calculated support of $2.64 and faces resistance near $3.36, while the 14‑day RSI of 41 suggests limited momentum but not yet oversold conditions. Although the MACD histogram is slightly positive and the line sits above the signal, the overall trend is classified as bearish and volume has been declining, amplifying the downside bias. Volatility remains elevated at more than 51% over the past 30 days and a beta of roughly 1.4 indicates the share moves more sharply than the market.
Fundamentally, YSG posted $4.30 billion of revenue with a healthy 78% gross margin and 20% year‑over‑year growth, yet operating profit is only 2.2% and the company recorded a net loss, reflected in a negative trailing EPS of –$0.12. Cash balances of $1.06 billion offset a modest debt load, but operating and free cash flow are negative and the debt‑to‑equity ratio is high at nearly 6, underscoring balance‑sheet pressure. Valuation metrics look attractive – a forward P/E of 5.2, price‑to‑book of 0.62 and price‑to‑sales of 0.06 – implying an estimated upside of over 160% versus current levels. However, the extreme‑greed market sentiment (Fear‑Greed Index 88.6) and a historical max drawdown of nearly 75% suggest that any rally carries significant risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Price below all major moving averages
  • Decreasing volume and high volatility
  • Proximity to support with limited upside

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and gross margins
  • Attractive valuation multiples (forward P/E ~5, P/B <1)
  • Balance‑sheet pressure from negative cash flows

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Potential for earnings turnaround as scale improves
  • Undervalued price relative to book and sales
  • Large upside target versus current market price

Key Metrics & Analysis

Financial Health

Revenue Growth20.10%
Profit Margin-1.88%
P/E Ratio5.2
ROE-3.03%
ROA-2.29%
Debt/Equity5.88
P/B Ratio0.6
Op. Cash Flow$-94663000
Free Cash Flow$-193681744

Technical Analysis

TrendBearish
RSI41.1
Support$2.64
Resistance$3.36
MA 20$3.02
MA 50$3.32
MA 200$5.90
MACDBullish
VolumeDecreasing
Fear & Greed Index88.61

Valuation

Target Price$7.65
Upside/Downside164.67%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.42
Volatility51.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.